The €3.8m acquisition of Spain's Allerpharma by UK-based Allergy Therapics was announced nine months ago and has recently been completed. The sale and purchase agreement includes an additional payment of up to €2M depending on the results obtained in 2016, so the sale could reach €5.8M. With the acquisition, Allergy Therapeutics absorbs Alerpharma and incorporates its employees into its current workforce.

About Alerpharma

Alerpharma Inmunal, based in Madrid, is a company dedicated to developing immunotherapy solutions for allergy and bacterial vaccines. Its main subsidiary is Inmunal, which was spun off from the biopharmaceutical company Zeltia and will continue to operate from its Madrid facilities.

Alerpharma bought Inmunal from the group Zeltia when two Zeltia group companies, Genómica and Pharma Gen, merged and Pharma Gen divested itself of businesses considered non-strategic, such as Inmunal.

About Allergy therapheutics

Allergy Therapeutics is a multinational biotechnology group specialising in the development of innovative therapies for the treatment and prevention of allergies. The group has more than 400 employees worldwide and specialises in the research, development and commercialisation of vaccines for immunotherapy and other allergy solutions.

The company is listed on the London Stock Exchange and is completing clinical trials of its lead product, Pollinex Quattro, for registration and launch in the United States, a market estimated to be worth more than $2 billion.

Reasons for purchase

Allergy Therapeutics had already been operating in Spain since 1999, which is its second largest market after Germany. With this acquisition, Allergy Therapheutics is able to improve control of its logistics in Spain, reduce costs and make the investment profitable by being able to carry out distribution from Madrid.

On the other hand, it will strengthen the consolidation of Allergy Therapeutics Ibérica in the Spanish market and thus reinforce its capacity to develop new vaccines, while allowing further progress in the research and development of new products.

In addition, Allergy Therapeutics will be able to incorporate new product lines already developed by Alerpharma, such as allergenic extracts and specific immunotherapy.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal with extensive experience in the biotech sector. Call us on + 34 944240141 or fill in the contact form.